Of Counsel Emily Wein was quoted in a Solution Reach article, “New Technology-Based Communication Codes Can Help Boost Patient Satisfaction,” about Medicare’s decision to begin paying for two services that provide patients with affordable and convenient options in lieu of a face-to-face visit with their doctor.
Although the payment amounts are nominal, the main impetus behind providing these services is to boost patient satisfaction and enhance health care quality and efficiency, Wein said. “These codes illustrate CMS’ willingness to support providers who are increasingly using technology to make care most cost-effective and satisfactory to patients,” she said.
Although the payment amounts are nominal, the main impetus behind providing these services is to boost patient satisfaction and enhance health care quality and efficiency, Wein said. “These codes illustrate CMS’ willingness to support providers who are increasingly using technology to make care most cost-effective and satisfactory to patients,” she said.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”